Group 1 - The company has planned an annual production capacity of 20,000 tons for lithium hexafluorophosphate (LiPF₆) and 10,000 tons for lithium bis(fluorosulfonyl)imide (LiFSI) [1] - Due to market conditions, the actual output of these products is limited [1] - The company does not currently produce PVDF-HFP water-based adhesives or sulfide electrolyte materials [1] Group 2 - The company has formed strategic partnerships with leading domestic and international manufacturers [1] - It leverages its technical expertise and production resources to provide differentiated and customized product services [1] - The company aims to develop and offer various competitive key chemicals in collaboration with its customers [1]

Core Points - On September 16, 2025, the company will hold a staff representative meeting in its conference room [2] - The staff representatives unanimously agreed to elect Mr. Fan Xiaobin as the employee representative director of the company's ninth board of directors [2]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 15% relative to the industry index in the next six months [4]. Core Viewpoints - The company's performance in the first half of 2025 exceeded market expectations, showing signs of recovery with a revenue increase of 5.76% year-on-year and a significant net profit growth of 1481.94% [1][2]. - The recovery in profitability from the agricultural protection business and significant growth in the pharmaceutical sector are key drivers of the company's improving performance [2][8]. - The company is focusing on expanding its overseas operations and enhancing its product offerings in the agricultural protection and pharmaceutical sectors, which are expected to contribute to long-term growth [8][9]. Financial Summary - **Revenue Forecast**: The company is projected to achieve revenues of 68.82 billion, 79.49 billion, and 90.29 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 21.2%, 15.5%, and 13.6% [9]. - **Net Profit Forecast**: Expected net profits are 4.09 billion, 5.81 billion, and 7.28 billion yuan for the same years, with growth rates of 297.0%, 42.0%, and 25.2% [9]. - **Earnings Per Share (EPS)**: The projected EPS for 2025, 2026, and 2027 are 0.44, 0.63, and 0.79 yuan, respectively [9]. - **Valuation Ratios**: The price-to-earnings (P/E) ratios are expected to be 25.6, 18.0, and 14.4 for the years 2025, 2026, and 2027 [9]. Business Segment Performance - **Agricultural Protection**: Revenue from agricultural intermediates was 17.02 billion yuan, with a year-on-year decline of 9.13%. However, the gross margin improved to 24.99%, up 9.48 percentage points year-on-year [2]. - **Pharmaceuticals**: The pharmaceutical segment saw revenue of 10.18 billion yuan, a year-on-year increase of 42.80%, with a stable gross margin [8]. - **New Energy**: The company has commercialized four new energy products and is advancing several others through various stages of development, indicating potential for a second growth curve [9].

Group 1 - The company, Lianhua Technology, announced the convening of its 9th First Board Meeting on September 16, 2025, to discuss the election of a director for company affairs [1] - For the first half of 2025, Lianhua Technology's revenue composition was 99.64% from industrial operations and 0.36% from other businesses [1] - As of the report date, Lianhua Technology's market capitalization was 10.2 billion yuan [1]

特此公告。 联化科技股份有限公司董事会 二〇二五年九月十七日 证券代码：002250 证券简称：联化科技 公告编号：2025-041 联化科技股份有限公司 关于选举第九届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 联化科技股份有限公司（以下简称"公司"）根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《联化科技股份有限公司章程》（以下简称"《公司章 程》"）等有关规定，公司于2025年9月16日在公司会议室召开职工代表大会。经 与会职工代表认真审议，一致同意选举樊小彬先生为公司第九届董事会职工代表 董事，任期自本次职工代表大会选举通过之日起至公司第九届董事会届满之日止。 樊小彬先生简历附后。 樊小彬先生符合《公司法》《公司章程》等法律法规和制度规定的董事任职 资格及条件。公司第九届董事会中兼任公司高级管理人员以及由职工代表担任的 董事人数总计不超过公司董事总数的二分之一。 附件： 樊小彬简历 樊小彬先生，中国国籍，1976年3月出生，硕士。历任联化科技监事、研发 中心副主任、农药与精细化学品研发部主任、总裁助理。兼任江苏 ...

证券代码：002250 证券简称：联化科技 公告编号：2025-040 联化科技股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议时间：2025年9月16日（星期二）15时00分 2、会议地点：浙江省台州市黄岩区江口经济开发区永椒路8号会议室 3、会议召集人：联化科技股份有限公司董事会 公司董事、监事、高级管理人员和见证律师出席或列席了会议，符合《公司法》 和《公司章程》的有关规定。 二、议案审议表决情况 本次股东大会按照会议议程，以现场记名投票与网络投票表决方式审议通过了 如下决议： 1、审议通过《关于修订<公司章程>及相关议事规则的议案》，该项议案获得出 席本次股东大会有效表决权股份总数的 2/3 以上通过。 表决结果： 4、会议方式：现场投票与网络投票相结合的方式 5、现场会议主持人：董事长王萍女士 6、会议的召集、召开与表决程序符合《公司法》《上市公 ...

北京市嘉源律师事务所 关于联化科技股份有限公司 2025年第一次临时股东大会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国·北京 北京市嘉源律师事务所 北京BEIJING·上海SHANGHAI·深圳SHENZHEN·香港HONG KONG·广州GUANGZHOU·西安XI'AN 致：联化科技股份有限公司 关于联化科技股份有限公司 2025年第一次临时股东大会的 法律意见书 嘉源(2025)-04-683 北京市嘉源律师事务所（以下简称"本所"）接受联化科技股份有限公司（以 下简称"公司"）的委托，根据《中华人民共和国公司法》（以下简称"《公司 法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公 司股东会规则》（以下简称"《股东会规则》"）等现行有效的法律、行政法规、 部门规章、规范性文件（以下简称"法律法规"）以及《联化科技股份有限公司 章程》（以下简称"《公司章程》"）的有关规定，指派本所律师对公司2025 年第一次临时股东大会（以下简称"本次股东大会"）进行见证，并依法出具本 法律意见书。 为出具本法律意见书，本所指派律师现场见证了本次股东大会，查阅了公司 提供的 ...

第九届董事会第一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 联化科技股份有限公司（以下简称"公司"）第九届董事会第一次会议通知 于2025年9月11日以电子邮件方式通知各董事（包括董事候选人）。会议于2025 年9月16日在联化科技会议室以现场与通讯表决相结合的方式召开。会议应出席 董事7人，实际出席董事7人。公司高级管理人员列席了本次会议，与会董事一致 推荐王萍女士主持会议，符合《公司法》、《证券法》等法律法规、部门规章、规 范性文件及《公司章程》的有关规定。会议形成如下决议： 一、会议以7票同意，0票反对，0票弃权的表决结果，审议并通过了《关于 选举董事长的议案》。 与会董事一致选举王萍女士为公司第九届董事会董事长，其任期自本次董事 会审议通过之日起至第九届董事会届满为止。 二、会议以7票同意，0票反对，0票弃权的表决结果，审议并通过了《关于 选举代表公司执行公司事务董事的议案》。 与会董事一致选举王萍女士为公司第九届董事会代表公司执行公司事务董 事，其任期自本次董事会审议通过之日起至第九届董事会届满为止。 三、会议以7票同意，0票反对 ...

Company Overview - Lianhua Technology Co., Ltd. is located in Taizhou, Zhejiang Province, established on September 14, 1998, and listed on June 19, 2008 [2] - The company operates in three main business segments: pesticides, pharmaceuticals, and functional chemicals, with revenue contributions of 54.03%, 32.32%, 8.42%, and 4.88% from equipment and engineering services, respectively [2] - As of June 30, 2025, the number of shareholders increased by 88.92% to 72,300, while the average circulating shares per person decreased by 47.07% to 12,533 shares [2] Financial Performance - For the first half of 2025, Lianhua Technology achieved a revenue of 3.15 billion yuan, representing a year-on-year growth of 5.76%, and a net profit attributable to shareholders of 224 million yuan, a significant increase of 1481.94% [2] - The company has distributed a total of 960 million yuan in dividends since its A-share listing, with 129 million yuan distributed over the past three years [3] Stock Market Activity - On September 16, Lianhua Technology's stock price fell by 2.03% to 11.12 yuan per share, with a trading volume of 182 million yuan and a turnover rate of 1.79%, resulting in a total market capitalization of 10.134 billion yuan [1] - Year-to-date, the stock price has increased by 102.55%, but it has seen a decline of 1.77% over the last five trading days and a drop of 17.38% over the past 60 days [1] - The company has appeared on the "Dragon and Tiger List" nine times this year, with the most recent appearance on June 25, where it recorded a net buy of -46.854 million yuan [1]

证券日报网讯联化科技（002250）9月15日在互动平台回答投资者提问时表示，公司与国内、国际市场 领先厂商形成战略合作，结合自有的技术特长和生产资源，为客户提供差异化、定制化的产品服务，与 客户共同成长，开发和提供了多种具有竞争力的关键化学品。 ...